Higher Risk of Recurrence, Worse Survival Related to Delayed Surgery in Veterans With Stage I NSCLC

Veterans diagnosed with stage I non–small cell lung cancer who have experienced delays in their surgical treatment over the past 12 weeks are at a higher risk of negative disease outcomes compared with those receiving surgery immediately after diagnosis.

Veterans with stage I non–small cell lung cancer (NSCLC) who have delayed surgical procedures for more than 12 weeks are at a higher risk of recurrence and worse survival versus immediate surgical treatment, according to a study published in JAMA Network Open.

The mean (standard deviation [SD]) of time to surgical treatment (TTS) was 70.1 (38.6) days. Investigators found recurrence in 42.0% of patients with the median follow-up of 6.15 years. For each week of delayed surgery beyond 12 weeks, recurrence increased by 0.4% (HR, 1.004; 95% CI, 1.001-1.006; P = .002). Veterans who had surgery within 12 weeks of diagnosis had better overall survival than those who delayed (HR, 1.132; 95% CI, 1.064-1.204; P < .001).

“This cohort study examined the association of delayed surgical treatment with oncologic outcomes in patients in the VHA [Veterans Health Administration] with clinical stage I lung cancer. Using a more robust and precise method for quantifying surgical delay…our study found that patients who waited more than 12 weeks for resection had an increased risk of recurrence,” wrote investigators of the study who were led by Brendan T. Heiden, MD.

There were 9904 veterans who met inclusion criteria, of whom 96.3% were men and 50.5% were smoking at the time of surgical treatment. There were 26.6% of patients who had a 0-day wait time between diagnosis and surgery.

In the population, 70.1% of veterans underwent a lobectomy and 53.3% had a minimally invasive incision. It was found that 52.9% of patients had adenocarcinomas and most had tumor grades greater than I, comprised of grade II (52.5%), grade III (33.0%), and grade IV (1.5%).

At 30 days, 2.1% of patients had died whereas 8.2% had been readmitted.

There was pathological upstaging in 12.3% of patients and positive surgical margins found in 3.1%. Patients who had higher odds of upstaging were younger in age (OR for every 1-year increase, 0.985; 95% CI, 0.975-0.996; P = .006), had higher tumor grade (OR, 3.145; 95% CI, 2.341-4.224; P < .001), had larger tumor size (OR, 1.734; 95% CI, 1.250-2.407; P = .03), had greater number of lymph nodes examined (OR, 1.476; 95% CI, 1.275-1.709; P = .009), or were treated with pneumonectomy vs lobectomy (OR, 3.528; 95% CI, 2.415-5.153; P < .001).

The factors that were associated with higher odds of positive surgical margins were wedge resections vs lobectomy (OR, 2.501; 95% CI, 1.866-3.352; P < .001) and larger tumor size (OR, 3.087; 95% CI, 1.651-5.771; P < .001). There was no significant association between radiologic TTS (RTTS) and upstaging or a resection of positive margins from.

The median time to recurrence was 1.24 years (interquartile range, 0.43-2.76). An increased risk of recurrence was associated with younger age (HR for every 1-year increase, 0.992; 95% CI, 0.987-0.997; P = .002), higher Charlson Comorbidity Index score (HR for every 1 unit increase, 1.055; 95% CI, 1.037-1.073; P < .001), segmentectomy vs lobectomy (HR, 1.352; 95% CI, 1.179-1.551; P < .001) or wedge resection vs lobectomy (HR, 1.282; 95% CI, 1.179-1.394; P< .001), higher tumor grade (HR, 1.210; 95% CI, 1.085-1.349; P < .001), larger tumor size (HR, 1.209; 95% CI, 1.051-1.390; P = .008), lower number of lymph nodes examined (HR, 0.866; 95% CI, 0.803-0.933; P < .001), higher pathologic stage (HR 1.571; 95% CI, 1.351-1.837; P < .001), and longer RTTS.

Factors associated with surgical procedure delay longer than 12 weeks were African American race (OR vs White race, 1.267; 95% CI, 1.112-1.444; P < .001), higher area deprivation index score (OR every 1 unit increase, 1.005; 95% CI, 1.002-1.007; P = .002), lower hospital case load (OR for every 1 unit increase, 0.998; 95% CI, 0.998- 0.999; P = .001), year of diagnosis (OR for each additional year, 0.900; 95% CI, 0.884-0.915; P < .001), and performance of a preoperative mediastinoscopy or endobronchial ultrasonography (OR, 1.385; 95% CI, 1.226-1.564; P < .001).

Investigators found that smoking status, Charlson-Deyo Comorbidity Index, and frailty were not associated with longer RTTS.

“These findings suggest that veterans with clinical stage I lung cancer who wait more than 12 weeks for resection may have an increased risk of recurrence and worse survival rates. Efforts to minimize delays in surgical procedures for lung cancer are essential to decrease the risk of disease recurrence and the associated worse prognosis,” concluded study investigators.


Heiden BT, Eaton DB Jr, Engelhardt KE, et al. Analysis of delayed surgical treatment and oncologic outcomes in clinical stage I non-small cell lung cancer. JAMA Netw Open. 2021;4(5):e2111613. doi:10.1001/jamanetworkopen.2021.11613

Related Videos
An expert from Yale School of Medicine discusses how the approval of adjuvant pembrolizumab expands treatment to include patients with IB, II, III, and IIIA resected, early-stage, non–small cell lung cancer regardless of PD-L1 expression.
Alexander Spira, MD, PhD, FACP, of the Virginia Cancer Specialists, discusses how the FDA approval of adagrasib for KRAS G12C–mutated non–small cell lung cancer can provide benefit for this patient population.
Pooling data with other radiation trials, looking more closely at central non-small cell lung cancer, and exploring secondary outcomes represent the next steps in terms of analyzing stereotactic body radiation (SBRT) vs conventional hypofractionated radiotherapy (CRT), according to Anand Swaminath, MD.
Anand Swaminath, MD, reviews the design of the phase 3 LUSTRE trial comparing a 3-week conventional radiotherapy regimen with stereotactic body radiotherapy among patients with stage I medically inoperable non-small cell lung cancer.
Stereotactic body radiation therapy yielded numerical improvements in terms of local control compared with conventional hypofractionated radiotherapy among patients with stage I medically inoperable non-small cell lung cancer, according to findings from the phase 3 LUSTRE trial.
Data from the phase 3 LUSTRE trial indicated that stereotactic body radiotherapy is a safe and effective alternative to conventional radiation for use in patients with stage I medically-inoperable non-small lung cancer, according to an expert from Juravinski Cancer Centre in Canada.
Hossein Borghaei, DO, MS, discussed where investigators may drive future research following the phase 2 Lung-MAP trial examining pembrolizumab and ramucirumab in previously treated advanced non–small cell lung cancer.
Hossein Borghaei, DO, MS, highlights data that read out of the phase 2 Lung-MAP trial, assessing ramucirumab/pembrolizumab in previously treated advanced non–small cell lung cancer.
Related Content